Theranostics

Introduction - See & Treat Magic

• Theranostics: A paradigm combining diagnostics (Dx) and therapy (Tx) using a single agent or platform.
• Core Principle: "See what you treat, treat what you see."
  • Diagnostic component visualizes the target (e.g., tumor, receptor).
  • Therapeutic component delivers treatment to the visualized target.
• Mechanism: Utilizes molecules that can be labeled with either an imaging isotope (for Dx) or a therapeutic isotope/drug (for Tx).
  • Often involves a targeting moiety (e.g., peptide, antibody) linked to a radionuclide.

• Goal: Personalized medicine - precise localization and targeted treatment, minimizing systemic toxicity.

⭐ Theranostics embodies the 'magic bullet' concept envisioned by Paul Ehrlich, aiming for highly specific drug delivery to diseased cells.

• Key advantage: Allows for patient selection, treatment planning, and monitoring response effectively.

Radiopharmaceutical Pairs - Dynamic Duos

Theranostics employs 'dynamic duos': a diagnostic radiopharmaceutical to visualize a target, and a therapeutic counterpart to treat it. Both agents bind to the same molecular entity. These pairs enable personalized medicine by confirming target presence before therapy.

📌 Iodine ($^{123}I$/$^{131}I$): Imaging and Internal radiotherapy for thyroid.

Key Clinical Uses - Cancer Combat Zones

• Prostate Cancer (PCa):

  • Target: Prostate-Specific Membrane Antigen (PSMA).
  • Diagnostic: $^{68}Ga$-PSMA PET/CT (staging, recurrence).
  • Therapeutic: $^{177}Lu$-PSMA (metastatic Castration-Resistant PCa, mCRPC).
  • Threshold: High PSMA expression on PET.

  ⭐ $^{177}Lu$-PSMA therapy shows significant survival benefits in mCRPC patients post prior therapy failure.

• Neuroendocrine Tumors (NETs):

  • Target: Somatostatin Receptors (SSTRs).
  • Diagnostic: $^{68}Ga$-DOTATATE/TOC PET/CT.
  • Therapeutic: Peptide Receptor Radionuclide Therapy (PRRT) with $^{177}Lu$-DOTATATE / $^{90}Y$-DOTATATE.
  • 📌 Mnemonic: 'DOTATATE targets SSTRs - Don't Hesitate, Radiate!'
  • Key: High SSTR expression; Ki-67 < 20% often preferred for PRRT.

• Differentiated Thyroid Cancer (DTC):

  • Target: Sodium-Iodide Symporter (NIS).
  • Diagnostic: $^{123}I$ or low-dose $^{131}I$ Whole Body Scan (WBS).
  • Therapeutic: High-dose $^{131}I$ (remnant ablation, metastatic disease).

• Flowchart: PSMA Therapy Selection for mCRPC

Dosimetry & Future - Scan, Plan, Advance!

• Dosimetry:
  • Calculates absorbed radiation dose (Gy) for personalized theranostics.
  • Utilizes imaging (SPECT/CT, PET/CT) & MIRD schema.
  • Optimizes tumor dose vs. normal tissue toxicity.
• Future Horizons:
  • Alpha-emitters ($^{225}Ac$, $^{213}Bi$): High LET, short-range for potent, localized kill.
  • New radiopharmaceuticals & targets.
  • AI in planning & response prediction.
  • Combination therapies (e.g., immunotherapy).

⭐ Alpha-emitters like $^{225}Ac$ are highly promising due to their high Linear Energy Transfer (LET) and short path length, delivering potent, localized cytotoxicity with minimal damage to surrounding healthy tissue. oka

High‑Yield Points - ⚡ Biggest Takeaways

• Theranostics uniquely combines diagnostic imaging and targeted radionuclide therapy.
• Core concept: "See what you treat, treat what you see", enabling personalized treatment.
• Lu-177 DOTATATE is pivotal for imaging and treating neuroendocrine tumors (NETs).
• Lu-177 PSMA targets prostate-specific membrane antigen (PSMA) in advanced prostate cancer.
• I-131 remains a cornerstone for both diagnosis and therapy of thyroid disorders.
• Radium-223 (Xofigo), an alpha-emitter, is used for bone metastases in prostate cancer.
• Enables patient-specific treatment selection and monitoring of therapeutic response.